Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06886477 · ClinicalTrials.gov registry record · NA

Sickle Cell, Pain and Mediterranean Diet

A NA study of Sickle Cell Disease and Sickle Cell, sponsored by University of Illinois at Chicago.

Active
Registry status
NA
Development phase
28
Enrollment target
1
Study location

NCT06886477: Active NA study of Sickle Cell Disease and Sickle Cell, sponsored by University of Illinois at Chicago.

NCT06886477 is a NA study of Sickle Cell Disease and Sickle Cell that is active but no longer recruiting, run by University of Illinois at Chicago. The registered enrollment target is 28 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06886477, a NA study of Sickle Cell Disease and Sickle Cell, is active but no longer recruiting, sponsored by University of Illinois at Chicago.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to compare pain levels in individuals with Sickle Cell Disease while following the Mediterranean Diet to pain levels while following their usual diet.

Primary Outcome

Mass spectrometry methods for butyrate, propionate, acetate

Interventions

  • OTHER Usual Diet
  • OTHER Mediterranean Diet

Study Locations (1)

Illinois

  • University of Illinois Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2025-05-01
Est. Completion 2026-12-31
Phase NA
University of Illinois at Chicago

430 total trials

What the registry record for NCT06886477 still lists

NCT06886477 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (90% lower).

The record links to 4 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Usual Diet is the first listed.

NCT06886477 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT06886477 about?

NCT06886477 is a clinical study titled "Sickle Cell, Pain and Mediterranean Diet". The goal of this study is to compare pain levels in individuals with Sickle Cell Disease while following the Mediterranean Diet to pain levels while following their usual diet.

What is the current status of trial NCT06886477?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 28 participants. The study started on 2025-05-01. Estimated completion is 2026-12-31.

What conditions does trial NCT06886477 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Sickle Cell, Sickle Cell Disease Without Crisis, Mediterranean Diet.

What interventions are being tested in trial NCT06886477?

The interventions under investigation include: Usual Diet (OTHER), Mediterranean Diet (OTHER).

Who is sponsoring clinical trial NCT06886477?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06886477 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06886477's enrollment target sits among peer trials

28 148th of 213 higher than 64 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06886477, the US trial registry maintained by the National Library of Medicine. NCT06886477 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.